CRIS Current Research Information System

TAVOLARI, SIMONA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.675
EU - Europa 1.966
AS - Asia 1.083
AF - Africa 146
SA - Sud America 18
OC - Oceania 3
Continente sconosciuto - Info sul continente non disponibili 1
Totale 5.892
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.659
GB - Regno Unito 419
CN - Cina 354
IT - Italia 326
SE - Svezia 322
SG - Singapore 279
DE - Germania 227
VN - Vietnam 225
CH - Svizzera 135
IE - Irlanda 127
IN - India 109
UA - Ucraina 79
FR - Francia 77
RU - Federazione Russa 55
TG - Togo 55
FI - Finlandia 44
JO - Giordania 35
ZA - Sudafrica 33
BE - Belgio 30
CI - Costa d'Avorio 29
EE - Estonia 26
BG - Bulgaria 24
ID - Indonesia 21
NG - Nigeria 17
CA - Canada 15
NL - Olanda 12
GR - Grecia 11
HR - Croazia 11
CL - Cile 8
PL - Polonia 8
KR - Corea 7
TR - Turchia 7
AT - Austria 6
HK - Hong Kong 6
IR - Iran 6
PS - Palestinian Territory 6
BR - Brasile 5
RO - Romania 5
SC - Seychelles 5
UZ - Uzbekistan 5
JP - Giappone 4
TN - Tunisia 4
AU - Australia 3
EC - Ecuador 3
ES - Italia 3
LT - Lituania 3
MY - Malesia 3
PT - Portogallo 3
SI - Slovenia 3
BD - Bangladesh 2
DK - Danimarca 2
HU - Ungheria 2
LB - Libano 2
PE - Perù 2
PH - Filippine 2
PK - Pakistan 2
RS - Serbia 2
SA - Arabia Saudita 2
TH - Thailandia 2
UG - Uganda 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AE - Emirati Arabi Uniti 1
BY - Bielorussia 1
CZ - Repubblica Ceca 1
EG - Egitto 1
IL - Israele 1
KW - Kuwait 1
MC - Monaco 1
MX - Messico 1
SK - Slovacchia (Repubblica Slovacca) 1
TW - Taiwan 1
Totale 5.892
Salva come PNG Salva come JPEG
Città #
Chandler 379
Southend 369
Singapore 249
Fairfield 245
Dong Ket 213
Ashburn 176
Houston 150
Santa Clara 133
Dublin 127
Bern 125
Princeton 115
Wilmington 113
Bologna 109
Ann Arbor 108
Woodbridge 108
Seattle 98
Cambridge 90
Boardman 82
Lomé 55
Jacksonville 47
New York 44
Nanjing 41
Helsinki 40
Westminster 38
Amman 35
Berlin 34
Padova 30
Abidjan 29
Beijing 28
Brussels 27
Jinan 26
Redmond 26
San Diego 25
Sofia 24
Jakarta 21
Rome 20
Milan 19
Medford 18
Abeokuta 17
Guangzhou 17
Frankfurt am Main 16
Shenyang 15
Mülheim 14
Changsha 12
Florence 12
Hebei 12
Turin 12
Zhengzhou 12
Fremont 11
Jiaxing 11
Toronto 11
Des Moines 10
Kuban 10
Nanchang 10
Saint Petersburg 10
Los Angeles 9
Olalla 9
Shanghai 9
Bühl 8
Dearborn 8
Norwalk 8
Redwood City 8
San Francisco 8
Haikou 7
Falls Church 6
Halhul 6
Hyderabad 6
Mountain View 6
Tianjin 6
Amsterdam 5
Bremen 5
Hong Kong 5
Kunming 5
London 5
Mahé 5
Mumbai 5
Ningbo 5
Phoenix 5
San Venanzo 5
São Paulo 5
Taiyuan 5
Vienna 5
Boydton 4
Council Bluffs 4
Fontanelice 4
Istanbul 4
Lappeenranta 4
Paris 4
Taizhou 4
Warsaw 4
Atlanta 3
Casalecchio di Reno 3
Castelfranco Emilia 3
Changchun 3
Chicago 3
Hangzhou 3
Kuala Lumpur 3
Lanzhou 3
Lausanne 3
Lisbon 3
Totale 4.059
Salva come PNG Salva come JPEG
Nome #
Adjuvant treatment in biliary tract cancer 211
Antitumoral efficacy of the protease inhibitor gabexate mesilate in colon cancer cells harbouring KRAS, BRAF and PIK3CA mutations 186
Antiprotease strategy in combination with gemcitabine as a putative novel therapeutic approach for pancreatic cancer treatment 183
219 MiR-21 expression correlates with prognosis in extrahepatic radically resected cholangiocarcinomas treated with gemcitabine-based adjuvant chemotherapy 175
Antiprotease strategy in pancreatic cancer treatment: emergence from a preclinical study. 173
Antitumoral Efficacy of Two Turmeric Extracts According to Different Extraction Methods in Hepatocellular Carcinoma Cell Lines 166
Specific Toxicity of Maintenance Olaparib Versus Placebo in Advanced Malignancies: A Systematic Review and Meta-analysis 164
Simple and dendritic cyclam derivative. Photophysical properties, effect of protonation and Zn++ coordination, preliminary screening as inhibitors of tumor cell growth 149
Membrane human equilibrative nucleoside transporter 1 is associated with a high proliferation rate and worse survival in resected intrahepatic cholangiocarcinoma patients not receiving adjuvant treatments 146
Membrane localization of human equilibrative nucleoside transporter 1 in tumor cells may predict response to adjuvant gemcitabine in resected cholangiocarcinoma patients 144
Angiogenesis modulation in human umbilical endothelial vein (HUVE) cells by selected polychlorobiphenyls congeners is mediated by estrogen receptor alpha (ERα) binding. 142
Annellated pyrrole compounds for cancer management 133
Genetic heterogeneity in cholangiocarcinoma: a major challenge for targeted therapies 133
IL-6 triggers malignant features in mammospheres from human ductal breast carcinoma and normal mammary gland 132
Licofelone, a dual COX/5-LOX inhibitor, induces apoptosis in HCA-7 colon cancer cells through the mitochondrial pathway independently from its ability to affect the arachidonic acid cascade. 130
Molecular and proteomic insight into Notch1 characterization in hepatocellular carcinoma 127
Fibroblasts isolated from common sites of breast cancer metastasis enhance cancer cell growth rates and invasiveness in an interleukin-6-dependent manner 126
In Reply 124
Annellated pyrrole compounds for cancer management 123
The decrease of cell membrane fluidity by the non-steroidal anti-inflammatory drug Licofelone inhibits epidermal growth factor receptor signalling and triggers apoptosis in HCA-7 colon cancer cells. 123
Immunomodulation by 17beta-estradiol in bivalve hemocytes. 121
Genomic And Genetic Characterization of Cholangiocarcinoma Identifies Therapeutics Targets for Tyrosine Kinase Inhibitors 119
INTRAHEPATIC CHOLANGIOCARCINOMA DEVELOPMENT IN A PATIENT WITH A NOVEL BAP1 GERMLINE MUTATION AND LOW EXPOSURE TO ASBESTOS 118
Selected polychlorobiphenyls congeners bind to estrogen receptor alpha in human umbilical vascular endothelial (HUVE) cells modulating angiogenesis 117
MiR-122/Cyclin G1 Interaction Modulates p53 Activity and Affects Doxorubicin Sensitivity of Human Hepatocarcinoma Cells. 117
The basal-like breast carcinoma phenotype is regulated by SLUG gene expression 116
Re: Effect of simvastatin on cetuximab resistance in human colorectal cancer with KRAS mutations. 114
Effect of the serine proteases inhibitor gabexate mesylate (GM) on the activity of gemcitabine (G) in cell lines of pancreatic cancer (PC) 108
Plasma membrane localization of human equilibrative nucleoside transporter 1 (hENT-1) to predict better outcome of adjuvant gemcitabine in cholangiocarcinoma (CC) patients. 106
Cholangiocarcinoma: Epidemiology and risk factors 105
null 99
The Protease Inhibitor Gabexate Mesylate Reduces Invasiveness and Angiogenesis in Pancreatic Cancer Cell Lines, Enhancing Gemcitabine Action 97
IN VIVO/IN VITRO AGED FIBROBLASTS TRIGGER MALIGNANT FEATURES IN NORMAL AND CANCER STEM/PROGENITOR CELLS OF THE MAMMARY GLAND 89
Carcinogenesis of Cholangiocarcinoma 83
How to choose between percutaneous transhepatic and endoscopic biliary drainage in malignant obstructive jaundice: An updated systematic review and meta-analysis 83
Plasma membrane localization of human equilibrative nucleoside transporter 1 (hENT-1) predicts better outcome of adjuvant gemcitabine in cholangiocarcinoma (CC) patients. 82
Intensive follow-up program and oncological outcomes of 278 biliary tract cancer patients after curative intent surgery: A single-center retrospective experience 79
The protease inhibitor gabexate Mesylate has antitumor effects and enhances gemcitabine action on pancreatic cancer cell lines 78
TUSC3 accelerates cancer growth and induces epithelial-mesenchymal transition by upregulating claudin-1 in non-small-cell lung cancer cells 77
Wilson disease, ABCC2 c.3972C > T polymorphism and primary liver cancers: suggestions from a familial cluster 76
Is post-transplant chemotherapy feasible in liver transplantation for colorectal cancer liver metastases? 75
Percutaneous radiofrequency ablation in intrahepatic cholangiocarcinoma: a retrospective single-center experience 71
Asbestos exposure as an additional risk factor for small duct intrahepatic cholangiocarcinoma: a pilot study 70
Immunotherapy in Pancreatic Cancer: Why Do We Keep Failing? A Focus on Tumor Immune Microenvironment, Predictive Biomarkers and Treatment Outcomes 70
Anti-EGFR monoclonal antibodies in advanced biliary tract cancer: A systematic review and meta-analysis 68
Asbestos and Intrahepatic Cholangiocarcinoma 62
The (Eternal) Debate on Microwave Ablation Versus Radiofrequency Ablation in BCLC-A Hepatocellular Carcinoma 61
Second-line treatment in advanced biliary tract cancer: Today and tomorrow 59
Molecular features and targeted therapies in extrahepatic cholangiocarcinoma: Promises and failures 54
Long Noncoding RNA SBF2-AS1 Is Critical for Tumorigenesis of Early-Stage Lung Adenocarcinoma 49
Circulating tumor DNA in biliary tract cancer: Current evidence and future perspectives 46
Evolution of the experimental models of cholangiocarcinoma 44
Nivolumab: an investigational agent for the treatment of biliary tract cancer 44
Targeting BRAF-Mutant Biliary Tract Cancer: Recent Advances and Future Challenges 43
Exposure to Asbestos and Increased Intrahepatic Cholangiocarcinoma Risk: Growing Evidences of a Putative Causal Link 42
Current and novel therapeutic opportunities for systemic therapy in biliary cancer 42
Immunotherapy in Pancreatic Cancer: Why Do We Keep Failing? A Focus on Tumour Immune Microenvironment, Predictive Biomarkers and Treatment Outcomes 38
Activated FGFR2 signalling as a biomarker for selection of intrahepatic cholangiocarcinoma patients candidate to FGFR targeted therapies 38
TNFalpha up-regulates SLUG via the NF-kappaB/HIF1alpha axis, which imparts breast cancer cells with a stem cell-like phenotype. 30
Intestinal Microbiota Increases Cell Proliferation of Colonic Mucosa in Human-Flora-Associated (HFA) Mice 27
Are FGFR and IDH1-2 alterations a positive prognostic factor in intrahepatic cholangiocarcinoma? An unresolved issue 25
Have We Found the “Holy Grail” That May Predict Response to Immunotherapy in Hepatocellular Carcinoma? 24
FGFR-targeted therapeutics: clinical activity, mechanisms of resistance and new directions. 19
Mutational Landscape of Cholangiocarcinoma According to Different Etiologies: A Review 14
Improvements in Systemic Therapies for Advanced Malignant Mesothelioma 10
Decreasing Albumin mRNA Expression in Cholangiocarcinomas along the Bile Duct Tree. 7
Totale 6.106
Salva come PNG Salva come JPEG
Categoria #
all - tutte 18.321
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 18.321
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020602 0 0 0 0 0 0 135 137 156 72 46 56
2020/2021688 119 40 18 24 7 33 22 40 69 36 35 245
2021/20221.143 100 35 63 83 75 39 26 57 109 95 234 227
2022/20231.586 166 232 91 186 99 108 31 99 250 41 103 180
2023/2024422 54 59 22 34 34 97 14 25 10 31 15 27
2024/2025869 70 209 163 122 199 82 24 0 0 0 0 0
Totale 6.106